From July 2016 NICE will gain decision power by saying yes, no or maybe to cancer drugs entering the...
Read moreThe methodology to be used within the cost-effectiveness HTA evaluations is likely to be based on a ...
Read moreSome governments have looked to collective procurement with other countries, to in theory result in ...
Read moreThere are now European platforms for seeking early scientific advice with multiple payer organisatio...
Read moreThe aim of MAPPs is to enable quicker access for patients whilst providing adequate and evolving evi...
Read moreBased on the current clinical data, the PCSK9 inhibitors are a vital new treatment option for patien...
Read moreIt is the responsibility of CCGs to manage their local drug budgets
Read moreThis article contains official prices at the ex-manufacturer, wholesaler and pharmacy selling price ...
Read moreThe proposal states that the CDF should become a "managed access" fund for new cancer dugs, with cle...
Read morePharmaceutical companies are now launching curative treatments, in addition to drugs which only mana...
Read more